Cover Image

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

Non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions (EGFRex20ins) is relatively resistant to the existing EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is a novel TKI that selectively targets EGFRex20ins and has demonstrated therapeutic efficacy in pretreated patients with tu...

Full description

Saved in:
Bibliographic Details
Main Authors: Kian, Waleed (Author) , Christopoulos, Petros (Author) , Remilah, Areen A. (Author) , Levison, Esther (Author) , Dudnik, Elizabeth (Author) , Shalata, Walid (Author) , Krayim, Bilal (Author) , Marei, Ranin (Author) , Yakobson, Alexander (Author) , Faehling, Martin (Author) , Kahala, Dolev (Author) , Sara Granot, Inbal (Author) , Levitas, Dina (Author) , Peled, Nir (Author) , Roisman, Laila C. (Author)
Format: Article (Journal)
Language:English
Published: 20 September 2022
In: Frontiers in oncology
Year: 2022, Volume: 12, Pages: 1-9
ISSN:2234-943X
DOI:10.3389/fonc.2022.1010311
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3389/fonc.2022.1010311
Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/articles/10.3389/fonc.2022.1010311
Get full text
Author Notes:Waleed Kian, Petros Christopoulos, Areen A. Remilah, Esther Levison, Elizabeth Dudnik, Walid Shalata, Bilal Krayim, Ranin Marei, Alexander Yakobson, Martin Faehling, Dolev Kahala, Inbal Sara Granot, Dina Levitas, Nir Peled and Laila C. Roisman
Description
Summary:Non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions (EGFRex20ins) is relatively resistant to the existing EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is a novel TKI that selectively targets EGFRex20ins and has demonstrated therapeutic efficacy in pretreated patients with tumors harboring these mutations.
Item Description:Gesehen am 06.12.2022
Physical Description:Online Resource
ISSN:2234-943X
DOI:10.3389/fonc.2022.1010311

Similar Items